Literature DB >> 1382837

Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines.

C L Sommers1, S E Heckford, J M Skerker, P Worland, J A Torri, E W Thompson, S W Byers, E P Gelmann.   

Abstract

We have previously observed that breast cancer cell lines could exhibit either epithelial or fibroblastic phenotypes as reflected by their morphologies and intermediate filament protein expression (C. L. Sommers, D. Walker-Jones, S. E. Heckford, P. Worland, E. Valverius, R. Clark, M. Stampfer, and E. P. Gelmann, Cancer Res., 49:4258-4263, 1989). Fibroblastoid, vimentin-expressing breast cancer cell lines are more invasive in vitro and in vivo (E. W. Thompson, S. Paik, N. Brunner, C. L. Sommers, G. Zugmaier, R. Clarke, T. B. Shima, J. Torri, S. Donahue, M. E. Lippman, G. R. Martin, and R. B. Dickson, J. Cell. Physiol., 150: 534-544, 1992). We hypothesized that a breast cancer cell with an epithelial phenotype could undergo a transition to a fibroblastic phenotype, possibly resulting in more invasive capacity. We now show that two Adriamycin-resistant MCF-7 cell lines and a vinblastine-resistant ZR-75-B cell line have undergone such a transition. Adriamycin-resistant MCF-7 cells express vimentin, have diminished keratin 19 expression, have lost cell adhesion molecule uvomorulin expression, and have reduced formation of desmosomes and tight junctions as determined by reduced immunodetection of their components desmoplakins I and II and zonula occludens (ZO)-1. Other MCF-7 cell lines selected for resistance to vinblastine and to Adriamycin and verapamil did not have these characteristics, indicating that drug selection does not invariably cause these phenotypic changes. In addition, to determine if vimentin expression in MCF-7 cells alone could manifest a fibroblastic phenotype, we transfected the full-length human vimentin complementary DNA into MCF-7 cells. Although vimentin expression was achieved in MCF-7 cells, it did not affect the phenotype of the cells in terms of the distribution of keratins, desmoplakins I and II, ZO-1, or uvomorulin or in terms of in vitro invasiveness. We conclude that vimentin expression is a marker for a fibroblastic and invasive phenotype in breast cancer cells but does not by itself give rise to this phenotype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382837

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

Review 1.  Mitochondrial ROS and cancer drug resistance: Implications for therapy.

Authors:  Imoh S Okon; Ming-Hui Zou
Journal:  Pharmacol Res       Date:  2015-08-11       Impact factor: 7.658

2.  Promoter-independent regulation of vimentin expression in mammary epithelial cells by val(12)ras and TGFbeta.

Authors:  Bradley Yates; Craig Zetterberg; Vaishali Rajeev; Michael Reiss; Susan R Rittling
Journal:  Exp Cell Res       Date:  2007-08-01       Impact factor: 3.905

3.  Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior.

Authors:  M J Hendrix; E A Seftor; R E Seftor; K T Trevor
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

Review 4.  Role of intermediate filaments in migration, invasion and metastasis.

Authors:  M J Hendrix; E A Seftor; Y W Chu; K T Trevor; R E Seftor
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

5.  Molecular analysis of two mammary carcinoma cell lines at the transcriptional level as a model system for progression of breast cancer.

Authors:  S Schiemann; M Schwirzke; N Brünner; U H Weidle
Journal:  Clin Exp Metastasis       Date:  1998-02       Impact factor: 5.150

6.  Phenotypic analysis of human fetal renal cells transformed by the SV40 large T antigen.

Authors:  S Zannoni; F Boudreau; C Asselin
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-09       Impact factor: 2.416

Review 7.  Intermediate filaments.

Authors:  M J Hendrix
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

8.  Pleomorphic carcinoma of the breast in a 17-year-old woman.

Authors:  Rin Yamaguchi; Maki Tanaka; Miki Yamaguchi; Takanaru Fukushima; Yuko Kaneko; Hiroko Otsuka; Shin Isobe; Hiroshi Terasaki; Osamu Nakashima; Masayoshi Kage; Hirohisa Yano
Journal:  Med Mol Morphol       Date:  2010-03-26       Impact factor: 2.309

9.  Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.

Authors:  David S Guttery; Rachael A Hancox; Kellie T Mulligan; Simon Hughes; Sinead M Lambe; J Howard Pringle; Rosemary A Walker; J Louise Jones; Jacqueline A Shaw
Journal:  Breast Cancer Res       Date:  2010-08-02       Impact factor: 6.466

10.  Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.

Authors:  Lydia Livas; Sumati Hasani; Natasha Kyprianou
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.